APC: Welcome (and welcome back) to our 2024 Corporate Patrons

Tattoos, legal counsel, and good info

If APC had a tattoo on its bicep — if we had a bicep, I mean — it might well read “Consult legal counsel.” read more →
State advocacy update

APC sent a letter to the New Mexico Board of Pharmacy this week commenting on its proposed amendments that would align the state with USP (good), but would also require that pharmacists ensure all flavors are inert (yikes). read more →
Board approves new officer succession

The APC Board of Directors has voted to name Gina Besteman (previously vice president) the board chair-elect after the resignation of Michelle Moser from the position. Besteman will assume the chair in January 2025. read more →
FDA is concerned about compounded GLP-1 dosing errors

Earlier this week APC received a letter from the FDA explaining the agency's concerns regarding dosing and patient usage of compounded semaglutide and tirzepatide. read more →
Did you get your Compounding Pharmacy Snapshot?

If you haven’t already, don’t forget to download and share the 2023-2024 edition of our Snapshot of Pharmacy Compounding in America. read more →
After report, FTC to sue PBMs

On Tuesday, the Federal Trade Commission released a scathing, two-years-in-the-making report about PBMs. read more →

January 19, 2024

Welcome (and welcome back) to our 2024 Corporate Patrons

This year, we have 36 Corporate Patrons signed on in support of APC, including 22 Tier Corporate Patrons.

January 19, 2024

Forget worms—save $300 with early-bird Owner Summit registration

The professional development event of the year for compounding pharmacy and facility owners and managers is back, and it’s better than ever.

January 19, 2024

They don’t know what they don’t know

It was another week of interesting reporting on GLP-1s—compounded, counterfeit, and commercially available. APC continues to field multiple media inquiries each week about the GLP-1 craze and compounding’s role in shortages.

January 12, 2024

New tools to educate prescribers on cBHT threat

We’ve got some new tools to help you educate and inform prescribers about the threat to compounded hormone therapy.

January 12, 2024

APC to FDA: Show your work (please?)

APC submitted comments this week on FDA’s Interim Policy on Compounding Using Bulk Drug Substances Under Section 503A of the Federal Food, Drug, and Cosmetic Act.

January 12, 2024

APC leaders talk MOU and more in FDA listening session

In a listening session with representatives from FDA’s Center for Drug Evaluation & Research this week, APC leaders again pressed FDA to support a proposal to eliminate the MOU on interstate shipments of compounded medications.

January 12, 2024

You say goodbye, I say hello …

This week, just two weeks into the new year, in a special-called APC Board of Directors meeting, I resigned as your 2024 APC Board Chair effective January 31. On February 1, I will join the APC staff as Chief Advocacy Officer.

January 5, 2024